A Combination Approach: Growing the Oncology Pipeline Through Innovation and Collaboration

May 30, 2018

A

t Bristol-Myers Squibb, researchers are working with urgency to discover and develop the next generation of cancer treatments. But they are not working in isolation. Every day, with colleagues as well as partners representing academic research centers, laboratories, clinicians, clinical trial organizations and biotech firms around the world, they are uncovering important information about the complex tumor microenvironment and its intersection with the immune system, which then informs the company’s deliberately-built pipeline.

Science

“There are numerous potential targets, combinations and biomarkers we could be studying in oncology research,” said David Feltquate, head of Oncology Early Clinical Development at Bristol-Myers Squibb. “In order to transform outcomes for as many patients as possible, we need to focus our efforts on the most promising areas of science within our walls and outside of the company so that we’re able to fill our pipeline in a purposeful manner and combine assets that make sense based on the science.”

Business Development in Our DNA

Bristol-Myers Squibb has long understood the importance of partnerships and business development in research. In fact, the company was built upon business development, when Bristol-Myers Company merged with Squibb in 1989. Today, the organization is engaged in more than 75 active partnerships and collaborations worldwide. 

Nils Lonberg and Alan Korman, leading I-O researchers and formerly of Medarex, continue to work at Bristol-Myers Squibb today, leading the antibody drug discovery team in Redwood City, CA.

Nils Lonberg and Alan Korman, leading I-O researchers and formerly of Medarex, continue to work at Bristol-Myers Squibb today, leading the antibody drug discovery team in Redwood City, CA.

When it comes to choosing industry partners, Bristol-Myers Squibb prioritizes long-term, reciprocal relationships that will ultimately enhance the pipeline with the most promising areas of science. For example, one of the organization’s first clinical oncology partnerships with Medarex – a pioneer in antibody engineering research – led to the eventual acquisition of the company, and subsequently, the approval of the first checkpoint inhibitors. The partnership-turned-acquisition model allowed both companies to collaborate, build key capabilities and evolve the science. The I-O foundation established through Medarex continues today, as Bristol-Myers Squibb works to engineer antibodies that may enhance the immune system’s ability to attack tumor cells. 

“The model we employed with Medarex fundamentally shifted our approach to business development,” said Paul Biondi, head of Business Development at Bristol-Myers Squibb. “We tend to focus on building strategic relationships with companies in the early phases of research, so we can all benefit from working together. Recent partnerships with Nektar, IFM and Five Prime are excellent examples of how we continue to partner with industry leaders to explore emerging areas of science and leverage our collective capabilities for patients.”

Precision Partnerships

The commitment to collaboration at Bristol-Myers Squibb extends beyond the assets in the pipeline. Partnerships with big data, diagnostic and technology companies enhance Bristol-Myers Squibb’s leading translational capabilities and offer complementary perspectives to help solve challenges in clinical research. As the company works to advance precision I-O, collaborations with companies like Flatiron Health and Foundation Medicine will continue to play a central role in the quest to deliver new medicines and diagnostics.  

“The future of cancer treatment is becoming more complex as we work to treat patients based on the biology of their tumor,” said Biondi. “There are multiple stakeholders involved in making precision I-O a reality. At the end of the day, we can work smarter, better and faster, if we work together.”

Oncology is just one piece of the puzzle. Across the portfolio, Bristol-Myers Squibb works with partners and collaborators to enhance the pipeline and explore biomarkers for autoimmune diseases, cardiovascular diseases and fibrosis as well. To learn more about partnering, visit: https://www.bms.com/researchers-and-partners/partnering.html

Related Content

Joining Forces to Advance Immuno-Oncology Research

Thomas Lynch

Advancing Translational Cancer Research—Together

Enlisting Allies in Strengthening Immune Response

Enlisting Allies in Strengthening Immune Response